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Tetyana Klymenko,1,5 Hartmut Döhner,2 Mark Cragg,6 Andrejs Braun,1 Pedro Cutillas,1,3 and John G. Gribben11Centre for
Haemato-Oncology, Barts
Cancer Institute, Queen Mary
University of London,
Charterhouse Square,
London, EC1M 6BQ, UK
2Department of Internal




Alderley Park, Alderley Edge,
Macclesfield, Cheshire, SK10
4TG, UK
4Center for Clinical Research,




City Campus, Howard Street,
Sheffield, S1 1WB, UK
6Antibody and Vaccine











The anti-CD20 monoclonal antibodies rituximab and obinutuzumab differ in their
mechanisms of action, with obinutuzumab evoking greater direct B cell death. To
characterize the signaling processes responsible for improved B cell killing by obi-
nutuzumab, we undertook a phosphoproteomics approach and demonstrate that
rituximab and obinutuzumab differentially activate pathways downstream of the
B cell receptor. Although both antibodies induce strong ERK and MYC activation
sufficient to promote cell-cycle arrest andB cell death, obinutuzumabexceeds ritux-
imab in supporting apoptosis induction bymeans of aberrant SYK phosphorylation.
In contrast, rituximab elicits stronger anti-apoptotic signals by activating AKT, by
impairing pro-apoptotic BAD, and by releasing membrane-bound NOTCH1 to up-
regulate pro-survival target genes. As a consequence, rituximab appears to rein-
force BCL2-mediated apoptosis resistance. The unexpected complexity and differ-
ences by which rituximab and obinutuzumab interfere with signaling pathways
essential for lymphoma pathogenesis and treatment provide important impetus
to optimize and personalize the application of different anti-CD20 treatments.
INTRODUCTION
Combination of the anti-CD20 monoclonal antibody rituximab with chemotherapy has significantly
improved outcomes for patients with CD20+ B cell lymphoma (Marshall et al., 2017). Despite this success,
the mechanisms of action of rituximab remain incompletely understood, largely because they are manifold
and encompass low levels of direct B cell killing next to immune-mediated effects (Marshall et al., 2017).
The latter are mainly mediated by complement recruitment, but they also comprise antibody-dependent
cellular cytotoxicity and phagocytosis (Marshall et al., 2017; Rouge et al., 2020). The clinical success of rit-
uximab has fostered the development of novel anti-CD20 antibodies such as obinutuzumab with stronger
capacity for direct B cell killing and a glycoengineered Fc-fragment for improved effector cell recruitment.
Higher efficiency in the induction of direct B cell death was achieved by introducing a sequence alteration
into the elbow-hinge region of the monoclonal antibody, rendering it more Type II, and so less able to clus-
ter CD20 in the membrane, reducing complement-dependent cytotoxicity when compared with rituximab
and other Type I monoclonal antibodies (Mossner et al., 2010). The molecular effects that this alteration has
on B cell signaling are relatively undocumented. A non-apoptotic lysosomal form of cell death has been
shown for obinutuzumab (Alduaij et al., 2011), whereas the limited degree of rituximab-induced cell death
has been associated with apoptosis following increased B cell receptor (BCR) signaling (Walshe et al., 2008;
Franke et al., 2011; Pavlasova et al., 2018).
Phase III clinical trials comparing rituximab and obinutuzumab head-to-head demonstrated superiority of
obinutuzumab over rituximab in the treatment of chronic lymphocytic leukemia (CLL; CLL11 trial,
ClinicalTrials.gov ID: NCT01010061) and follicular lymphoma (GALLIUM trial, ClinicalTrials.gov ID:
NCT01332968) with regard to minimal residual disease negativity, progression-free survival (PFS), and in
the case of CLL, overall survival (Goede et al., 2014, 2015; Marcus et al., 2017). However, in first-line treat-
ment of diffuse large B cell lymphoma (DLBCL; GOYA trial; ClinicalTrials.gov ID: NCT01287741), obinutu-
zumab failed to show benefit over rituximab (Vitolo et al., 2017). The reasons for non-superiority of obinu-
tuzumab in DLBCL treatment remain unresolved, partly due to a limited understanding of biomarkers
predicting response to rituximab or obinutuzumab.iScience 24, 102089, February 19, 2021 ª 2021 The Authors.





ArticleOne biomarker identified to predict decreased benefit from the addition of rituximab to fludarabine and
cyclophosphamide in CLL treatment is the presence of NOTCH1 mutation (Stilgenbauer et al., 2014). In
contrast, obinutuzumab maintains beneficial effects in this CLL subgroup (Estenfelder et al., 2016). How
the membrane-bound transcription factor NOTCH1 can interfere with rituximab-based chemoimmuno-
therapy is also unknown. NOTCH1 releases its intracellular domain (NICD1) after two cleavage steps
executed by the disintegrin and metalloproteinases ADAM10 or ADAM17 and by the g-secretase complex
to up-regulate genes involved in B cell survival and resistance to apoptosis, proliferation, and differentia-
tion (Borggrefe and Oswald, 2009; Fabbri et al., 2017; Santos et al., 2007). In B cell malignancies, most
NOTCH1 mutations result in a disruption of the PEST domain responsible for NICD1 inactivation and
degradation (Fabbri et al., 2011; Weng et al., 2004; Stilgenbauer et al., 2014).
To characterize B-cell-intrinsic signaling events following rituximab and obinutuzumab treatment, we
applied liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based phosphoproteomics. We
thereby uncovered an activation of pathways downstream of the BCR by rituximab as well as obinutuzumab
treatment, identified differences between the two monoclonal antibodies, and discovered links between
anti-CD20 treatment and NOTCH1 arising from an activation of the BCR signaling cascade.
RESULTS
Activation of BCR signaling
First, to validate a functionally relevant increase in BCR signaling by rituximab treatment, we measured
CCL4 and CCL3 expression as established surrogates for BCR activation (Takahashi et al., 2015). Transcrip-
tion of both genes was up-regulated following rituximab treatment (p < 0.0001). An increase in CCL4 and
CCL3 expression was also observed after treating with rituximab F(ab’)2 fragments (p < 0.001), but not tras-
tuzumab (Figure 1) demonstrating that the induction of BCR signaling was specific for CD20 binding and
not engagement of the inhibitory FcgRIIB. R406 treatment to inhibit the spleen tyrosine kinase (SYK)
reduced basal CCL4 and CCL3 expression levels (p < 0.01), diminished the increase in CCL3 expression af-
ter rituximab treatment (mean fold changes 20.2 versus 3.8; p < 0.001), and completely abrogatedCCL4 up-
regulation by rituximab (Figure 1), positioning signal generation by rituximab toward the proximal BCR
signaling cascade. Increased BCR signaling as inferred by CCL4 expression was also observed in MEC1
as well as in primary CLL cells after rituximab treatment (Figure S1).
To refine our understanding of rituximab-induced signaling events within the BCR signaling cascade and
compare them with signals generated by obinutuzumab treatment, we used LC-MS/MS-based phospho-
proteomics to analyze SU-DHL4 lymphoma cells after treating with rituximab or obinutuzumab for 1 or
24 h. Considering the two time points in both treatment arms relative to untreated control samples, we
identified 41 protein kinases after rituximab and 40 protein kinases after obinutuzumab treatment with
significantly altered activity as inferred by KSEA. Thirty-two of these kinases were affected by both rituxi-
mab and obinutuzumab, suggesting a high concordance between the signaling pathways modified by
both antibodies (Figure 2). Pathway enrichment analyses of the affected kinases revealed activation of
pathways belonging to the BCR signaling cascade and down-regulation of cell cycle progression subse-
quent to both antibody treatments (Table S1).
Excessively strong signals from the BCR lead to autoimmune checkpoint activation, cell-cycle arrest, and B
cell apoptosis as a physiologic mechanism to negatively select B cells with a specificity for autoantigens
(Muschen, 2018). To explore the hypothesis that rituximab and obinutuzumab hijack this mechanism to
elicit direct B cell killing, we next analyzed ERK, SYK, and the PI3K in more detail, as strong activation of
these three kinases has been shown to drive B cell selection (Muschen, 2018).
Differences between rituximab and obinutuzumab
The kinase with the strongest increase in activity at the 1 h time point after antibody treatment was iden-
tified as MEK, responsible for ERK activation (Figure 2). Consistently, ERK1 Thr202/Tyr204 and ERK2 Thr185/
Tyr187 in the kinase activation loops had highly increased phosphorylation levels at this time point (4-fold
and >10-fold increase, respectively; Figure 3A). The 24 h time point revealed lasting activity in theMEK-ERK
signaling axis after rituximab treatment, whereas this longevity was not observed for obinutuzumab. The
ERK target site MYC Ser62 had a 2-fold increase in phosphorylation at the 24 h time point uncovering acti-
vation of the MYC transcription factor. However, at the same time point, we also observed increased levels
of Thr58/Ser62 doubly phosphorylated MYC (4- to 5-fold) representing an already de-activated form of the2 iScience 24, 102089, February 19, 2021
Figure 1. Rituximab activates B cell receptor signaling as inferred by CCL4 and CCL3 expression
(A–D) CCL4 (A + B) and CCL3 (C + D) expression was assessed in SU-DHL4 cells by qRT-PCR after 150-min treatment with
rituximab (R), rituximab F(ab‘)2 fragments (R F(ab‘)2), or with trastuzumab (Tra) relative to untreated control samples (Ctrl).
Where applicable (B + D), cells were treated with the SYK inhibitor R406 or with DMSO vehicle control (Ctrl) for 48 h.
Statistical significance was tested by unpaired parametric t tests based on 3 biological replicates for each treatment
condition. Mean with range is plotted. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, ns = not significant, as calculated by




Articleshort-lived transcription factor (Figure 3B). In the absence of pro-survival stimuli, strongMYC activation can
re-enforce apoptosis induction (Hoffman and Liebermann, 2008).
SYK kinase activity was not significantly altered, although rituximab or obinutuzumab treatment increased
the phosphorylation level of 11 and 9 SYK residues, respectively. The phosphorylation sites included SYK
Tyr352 but not SYK Tyr525/526 located in the kinase activation loop (Figures 4A and S2). This constellation of
phosphorylated Syk residues has previously been associated with B cell apoptosis (Muschen, 2018). We
confirmed a lack of SYK Tyr525/526 phosphorylation after obinutuzumab treatment by immunoblotting,
but revealed low levels of SYK Tyr525/526 phosphorylation by rituximab (Figure 4B).
Activation of the lipid kinase phosphatidylinositol 3-kinase (PI3K) was inferred by changes in the phosphor-
ylation level of PI3K binding sites on CD19 and BCAP and by activity changes of downstream PI3K effectors
(Werner et al., 2010). Increased tyrosine phosphorylation levels on CD19 and BCAP implied PI3K activation
by rituximab as well as obinutuzumab, whereby more pronounced phosphorylation on CD19 Tyr500 after
rituximab was suggestive of stronger PI3K activation following this treatment (Figure S3). However, of
the three PI3K effectors MTOR, PDK1, and AKT, only AKT was found to be more active at the 1 h time point
after rituximab treatment (Figure 2), likely resulting from direct AKT activation by Ca2+ flux followingiScience 24, 102089, February 19, 2021 3
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Figure 2. Kinase activity changes after rituximab or obinutuzumab treatment
SU-DHL4 cells were treated with 5 mg/mL rituximab (R) or obinutuzumab (O) for 1 h (R1 and O1; left) or 24 h (R24 and O24;
right), and changes in kinase activities were inferred relative to untreated controls. The heatmaps show the Z score
enrichment of substrate groups for the different kinases calculated by the KSEA algorithm. Kinases belonging to the
KEGG pathway ‘‘B-cell receptor signaling’’ are indicated in red, and those belonging to the KEGG pathway ‘‘cell cycle’’
are indicated in blue. Peptides: number of peptides containing a phosphorylation site regulated by respective kinase;
Target sites: number of phosphorylation sites measured for respective kinase; Target proteins: number of proteins that
the phosphorylation sites regulated by the respective kinase map to. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 as




Articletreatment with type I but not type II anti-CD20 monoclonal antibodies (Walshe et al., 2008; Yano et al.,
1998). To validate AKT activation we assessed phosphorylation of AKT Thr308 and Ser473 by immunoblotting
due to lack of evidence in our LC-MS/MS data. Although AKT Thr308 phosphorylation was not observed
(data not shown), we found a strong increase in AKT Ser473 phosphorylation at 1 h after rituximab and rit-
uximab F(ab’)2 treatment with fading signals at the 24 h time point (Figure S4). This result corresponded
with phosphorylation of the AKT target site PRAS40 Thr246. Only low levels of phospho-AKT Ser473 were
detected after obinutuzumab treatment and no increase in AKT Ser473 phosphorylation was observed after
isotype control trastuzumab treatment (Figure 5A).
Because of the known powerful pro-survival effects of AKT (Werner et al., 2010), the differing ability of
rituximab and obinutuzumab to activate this kinase constituted a decisive difference between the two
monoclonal antibodies at the molecular level. Consistently, BAD Ser99, as an important AKT target
site with key role in inhibition of apoptosis, was found phosphorylated only after rituximab treatment
(p = 0.024; 1 h). In addition, rituximab more than obinutuzumab increased levels of Ser118 phosphoryla-
tion on BAD (p = 0.0074 at 1 h; p = 0.0007 at 24 h; Figure 5B). Phosphorylation on Ser99 and Ser118 se-
questers pro-apoptotic BAD in the cytosol and impairs its inhibitory effects on anti-apoptotic BCL2 and
BCL-xL so that rituximab more than obinutuzumab may diminish direct B cell death by reinforcing BCL2-
mediated anti-apoptotic signals (Masters et al., 2001; Zha et al., 1996). In line with this notion, SU-DHL4
cell viability was more strongly decreased by obinutuzumab than rituximab treatment (Alduaij et al.,
2011; Herter et al., 2013).
Links between BCR and NOTCH1 signaling
We next sought to understand the link between rituximab treatment and NOTCH1 signaling. Based on
publications showing increased ADAM activity upon Ca2+ flux and PI3K/MAPK-dependent phosphoryla-
tion changes (Herzog et al., 2014; Fan et al., 2003; Zhang et al., 2006; Li et al., 2018), we hypothesized
that anti-CD20 monoclonal antibodies could enhance ADAM10/ADAM17-mediated NOTCH1 cleavage.
To quantify short-term rises of NOTCH1 signaling, we assessed expression changes of its target gene
HES1 by qRT-PCR. Results obtained for rituximab and its control antibodies in SU-DHL4 cells correlated
with BCR activation after rituximab treatment, as demonstrated by CCL4 expression (Figure 6A). An in-
crease in HES1 expression after rituximab treatment was also validated in primary CLL cells (Figure S5).
The increases in HES1 expression observed after rituximab treatment in SU-DHL4 cells matched those induced
bySB2H2 treatment,which cross-links andactivates the IgGBCRof SU-DHL4directly (Figure 6B). Abolishment of
Ca2+ flux and BCR signaling by R406 completely abrogated the increase inHES1 and CCL4 expression after rit-
uximab exposure (Figure 6C). Treatment with the PI3K inhibitor idelalisib and the BTK inhibitor ibrutinib clearly
reduced nuclear NICD1 protein levels without obvious difference between both drugs (Figure 6D), but did not
prevent the increase in HES1 expression after rituximab treatment (Figure S6).
Direct comparisonof rituximabandobinutuzumab treatments in SU-DHL4 cells revealed amuch subtler increase
inHES1 expression following obinutuzumab treatment despite a comparable increase inCCL4 expression (Fig-
ure 7A). This result was consistent with a role for Ca2+ flux duringNOTCH1 activation (Le Gall et al., 2009; Arruga
et al., 2020). In addition, LC-MS/MS data revealed significant de-phosphorylation of ADAM17 Ser791 only after
rituximab treatment (p=0.048; Figure 7B), which has been shown previously to enhance the activity of ADAM17
(Fan et al., 2003). The kinetics of ADAM17 Ser791 de-phosphorylation followed those observed in the PI3K/AKT
pathway suggesting positive feedback from this pathway to the NOTCH1 receptor.
We finally validated NOTCH1 activation by rituximab at protein level. Western blot analysis for NICD1
showed increased NOTCH1 signaling after rituximab treatment in SU-DHL4 cells and three independentiScience 24, 102089, February 19, 2021 5
Figure 3. Rituximab and obinutuzumab induce ERK and MYC phosphorylation capable to induce B cell death
(A) Calculated areas under the curve (AUC) for phosphopeptide ions dually phosphorylated on ERK1 Thr202/Tyr204 (left)
and on ERK2 Thr185/Tyr187 (right) after treatment with rituximab (R) or obinutuzumab (O) for 1 or 24 h. Each of the three
plotted biological replicates depict the average of the two analytical replicates. Phosphorylation changes were tested for
statistical significance by unpaired non-parametric t tests calculated toward untreated control samples (Ctrl). Significant
phosphorylation is indicated in red; significant de-phosphorylation is indicated in blue.
(B) Calculated AUCs for phosphopeptide ions phosphorylated on MYC Ser62 (left) and dually phosphorylated on MYC
Thr58/Ser62 (right).





ArticleCLL cases (Figure S7). However, increased NOTCH1 signaling after treatment with rituximab F(ab’)2 frag-
ments was inconsistently observed in primary CLL cells. This may be afforded by heterogeneous basal ac-
tivity levels of the NOTCH1 receptor as well as in the B cell receptor signaling cascade. In contrast to results
obtained with the SU-DHL4 cell line, trastuzumab treatment increased NOTCH1 cleavage in all three pri-
mary CLL samples. Trastuzumab binds to the Fc gamma receptor expressed on immune effector cells, and
we hence reasoned that in addition to B cell-intrinsic modes of NOTCH1 activation, cleavage of NOTCH1
may, furthermore, be enhanced by effector cell activation. To address this hypothesis, we correlated the
increase in HES1 expression in eight independent CLL samples with the respective increase in CCL2
expression (Figure S8). The latter was used as a surrogate marker for the presence of activated monocytes
(Schulz et al., 2011). Our results supported a positive correlation between the extent of monocyte activation
and NOTCH1 signaling strength (R2=0.79; p<0.0001), which may result from a recruitment of NOTCH1
ligand expressing monocytes to CLL cells and/or from an activation of B cell-intrinsic signaling pathways
subsequent to a release of signaling molecules into the culture medium by activated effector cells
(Lopez-Guerra et al., 2020).6 iScience 24, 102089, February 19, 2021
Figure 4. Obinutuzumab exceeds rituximab in supporting apoptosis induction by means of aberrant SYK
phosphorylation.
(A) Calculated AUCs for phosphopeptide ions containing the phosphorylation site Tyr352 on SYK. Line indicates mean.
*p<0.05, **p<0.01, as calculated by unpaired non-parametric t tests.
(B) Immunoblot detection of phospho-SYK Tyr352 and phospho-SYK Tyr525/Tyr526 in SU-DHL4 cells treated with 2.5 mg/ml
rituximab (R) or obinutuzumab (O) for 1 h relative to untreated control samples (Ctrl; shown are representative results from





Our results demonstrate that rituximab and obinutuzumab both hijack the BCR signaling cascade, but in
different directions. Excessive ERK and MYC activation by riyuximab and obinutuzumab treatment sup-
ported the hypothesis that both anti-CD20 monoclonal antibodies induce direct cell killing via signals
generated in the BCR signaling cascade (Muschen, 2018; Hoffman and Liebermann, 2008). However, as
demonstrated by an aberrant SYK phosphorylation pattern, obinutuzumabmore effectively shifted the bal-
ance of these signals toward death, whereas rituximab engaged stronger signals associated with survival,
comprising pro-survival SYK Tyr525/526 phosphorylation, AKT activation, BAD Ser99 and Ser118 phosphory-
lation, and NOTCH1 activation. The stronger activation of NOTCH1 by rituximab acts in concert with AKT
activation, because BCL2 is a target gene of the NICD1 transcription factor and up-regulated BAD tran-
scription has been observed in CLL with overactive NOTCH1 signaling (Fabbri et al., 2017). Hence, it ap-
pears that rituximab can reinforce BCL2-mediated apoptotic resistance at both the protein and gene
expression levels thereby diminishing the degree of B cell killing (Werner et al., 2010; Fabbri et al.,
2017). PEST-domain NOTCH1 mutations therefore should reinforce pro-survival signals after rituximab
treatment due to their activating effect on NICD1 potentially explaining the reduced benefit of adding rit-
uximab to chemotherapy in NOTCH1 mutant CLL (Stilgenbauer et al., 2014; Weng et al., 2004).
Clinical trial data suggest that our results could influence clinical practice. CLL and follicular lymphoma, which
benefit from the use of obinutuzumab, are both characterized by high-level BCL2 expression (Goede et al.,
2014, 2015;Marcus et al., 2017), whereasDLBCL is amore heterogeneous entity (Schmitz et al., 2018). Focusing
on germinal center B cell-type DLBCL encompassing a considerable number of cases with genetic alterations
affecting BCL2 family members revealed a trend toward PFS improvement using obinutuzumab (Vitolo et al.,
2017; Schmitz et al., 2018). In contrast, PFS analysis within the activated B cell (ABC-)type DLBCL showed
almost identical results for both treatment arms, which may be afforded by frequent co-occurrence of genetic
aberrations affecting BCL2 family members with those affecting proximal BCR signaling (Vitolo et al., 2017;
Schmitz et al., 2018). The latter have been associated with chronic active BCR signaling bringing about a lower
capacity for rituximab and obinutuzumab to alter intrinsic B cell signals (Schmitz et al., 2018), hence likely
reducing the molecular advantages observed for obinutuzumab. Considering these observations, our results
warrant refined analyses of respective trial cohorts to identify biomarkers indicating where obinutuzumab
should become standard of care in the treatment of B cell lymphoma.
BCR signaling is a driver of lymphomagenesis (Niemann and Wiestner, 2013) to the extent that its acti-
vation bears the risk of providing growth stimuli to lymphoma cells if the apoptotic threshold is not
reached. This risk is higher using rituximab, which may be reflected in loss of CD20 expression at relapse
post rituximab treatment if lymphoma cells fail to reach the threshold because of (ultra-)low CD20
expression (Hiraga et al., 2009; Tomita, 2016). Moreover, the increase in BCR signaling after anti-CD20
treatment interacts with the modes of action of concomitant drugs. Response to cell cycle-dependent
cytostatic agents may be reduced by an arrest in the cell cycle, and targeting CD20 as well as BTK
may lead to partial antagonization of each other’s effects, providing a rationale for the lack of PFSiScience 24, 102089, February 19, 2021 7
Figure 5. Rituximab more than obinutuzumab induces pro-survival signals
(A) Immunoblot detection of phospho-AKT Ser473 and phospho-PRAS40 Thr246 in SU-DHL4 cells treated with 2.5 mg/ml
rituximab (R), rituximab F(ab‘)2 fragments (R F(ab‘)2), trastuzumab (T), or obinutuzumab (O) for 1 h relative to untreated
control samples (Ctrl). Shown are representative results from one of four experiments.
(B) Calculated AUCs for phosphopeptide ions containing the phosphorylation site Ser99 (top) or Ser118 (bottom) on BAD. Line




Articleimprovement observed in CLL after adding rituximab to ibrutinib treatment (Burger et al., 2019). In
contrast, PI3K and BCL2 inhibitors likely exert complementary effects on anti-CD20 therapy. Our results
thus provide new explanatory approaches for therapy resistance in B cell lymphoma treatment and help
to refine patient selection for rituximab or obinutuzumab and to improve drug sequencing within anti-
CD20 monoclonal antibody containing treatment protocols.
Furthermore, we identify themembrane-bound transcription factor NOTCH1 as a connective link between the
BCR signaling cascade and genes promoting B cell survival and proliferation. NOTCH1 cleavage upon Ca2+
flux allows rapid NICD1 release after BCR activation, and modulation of ADAM17 cleavage activity by (de-)
phosphorylation allows an adjustment ofNOTCH1 signaling strength. ADAM10was shown to cleaveNOTCH1
after ligand binding, whereas ADAM17 has been associated with ligand-independent NOTCH1 activation
(Bozkulak and Weinmaster, 2009). Activation of ADAM17 by signals generated through an (auto-)active BCR
may therefore explain high NICD1 protein levels observed in NOTCH1 wild-type peripheral blood CLL cells
that lack contact to NOTCH1 ligands (Fabbri et al., 2017). Moreover, our data suggest that NOTCH1 cleavage
in B cells is also dependent on the level of immune effector cell activation in themicroenvironment allowing an
adaption of NOTCH1 signaling in B cells to the degree of inflammation. Taken together, our results warrant
more detailed studies aiming at a better understanding of ADAM10/17 regulation in B cells to exploit the un-
derlying mechanisms for effective suppression of NOTCH1 signaling.
In conclusion, our results demonstrate unexpected complexity by which rituximab and obinutuzumab inter-
fere with signaling pathways essential for B cell lymphoma pathogenesis and treatment. This new insight
provides impetus to better personalize the choice of rituximab or obinutuzumab for anti-CD20 treatment,
to optimize the design of protocols encompassing anti-CD20 monoclonal antibodies, and to develop new
strategies for the treatment of NOTCH1-driven B cell lymphoma.
Limitations of study
A limitation of the study is that B cell-intrinsic signaling processes after anti-CD20 treatment have been deter-
mined in one cell line only and that the results obtained therefore lack evidence for general applicability. The
work is hypothesis generating andpaves theway toward subsequent studies addressing each conclusiondrawn.
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Figure 6. NOTCH1 and BCR signaling are synergized
(A)HES1 (left) andCCL4 (right) expression was assessed in SU-DHL4 cells by qRT-PCR after 150 min treatment with 2.5 mg/
ml rituximab (R), rituximab F(ab‘)2 fragments (R F(ab’)2), or trastuzumab (T) relative to untreated control samples (Ctrl).
Statistical significance was tested by unpaired non-parametric t tests based on 8 biological replicates for the control
samples and 4 biological replicates for each treatment condition.
(B)HES1 andCCL4 expression in SU-DHL4 cells after 150min of treatment with 2.5 mg/ml rituximab (R) or SB2H2 relative to
untreated control samples (Ctrl).
(C) HES1 expression in SU-DHL4 cells pre-treated with vehicle control (Ctrl, left) or R406 (5 mM; right) before treatment
with 2.5 mg/mL rituximab (R) for 150 min.
(D) Immunoblot detection of nuclear NICD1 protein levels in SU-DHL4 cells (left) and MEC1 cells (right) after 48 h
treatment with ibrutinib (IBR; 1 mM) or idelalisib (IDE; 5 mM) relative to samples treated with vehicle control (Ctrl). Shown
are representative results for one of four experiments on SU-DHL4 cells and one of two experiments on MEC1 cells. Mean
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Figure 7. Rituximab induces NOTCH1 signaling more strongly than obinutuzumab
(A) HES1 (left) and CCL4 (right) expression in SU-DHL4 cells after 150 min of treatment with 2.5 mg/ml rituximab (R) or
obinutuzumab (O) relative to untreated controls (Ctrl). Mean with range is plotted.
(B) Calculated AUCs for phosphopeptide ions containing the phosphorylation site Ser791 on ADAM17. Line indicates
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Validation of activated B-cell receptor signaling by rituximab treatment in MEC1 cells and
two primary CLL samples.
Related to Figure 1.
CCL4 expression was assessed in MEC1 cells (A) and in primary CLL cells (B + C) after 150
minutes of treatment with rituximab (R) or rituximab F(ab‘)2 fragments (R F(ab‘)2) relative to
untreated control samples (Ctrl). Statistical significance was tested by unpaired parametric t-tests
based on 3 biological replicates for each treatment condition in the case of MEC1 cells and
based on 5 biological replicates in the case of primary CLL samples. Mean with range is plotted.
















































































































































































































































SYK phosphorylation after rituximab or obinutuzumab treatment.
Related to Figure 4.
Calculated AUCs for phosphopeptide ions containing the phosphorylation sites indicated above


























































































































CD19 and BCAP phosphorylation after rituximab or obinutuzumab treatment.
Related to Figure 5.
Calculated AUCs for phosphopeptide ions containing the phosphorylation sites indicated above
on CD19 (top) or BCAP (bottom). Line indicates mean. *<0.05, **<0.01, ***<0.001, ns = not
significant; as calculated by unpaired non-parametric t-tests.
Supplementary Figure S4:
AKT activation was restricted to early time-points after rituximab treatment.
Related to Figure 5.
Immunoblot detection of phospho-AKT Ser473 in SU-DHL4 cells treated with rituximab (R),
rituximab F(ab‘)2 fragments (R F(ab‘)2), or trastuzumab (T) for one hour (left) or 24 hours (right)
























































































































Validation of activated NOTCH1 signaling by rituximab treatment in two primary CLL
samples.
Related to Figure 6.
HES1 and CCL4 expression was assessed in primary CLL cells after 150 minutes of treatment
with rituximab (R) relative to untreated control samples (Ctrl). Statistical significance was tested
by unpaired parametric t-tests based on 5 biological replicates for each treatment condition.





















































Treatment with ibrutinib or idelalisib did not prevent the increase in NOTCH1 signaling
after rituximab treatment.
Related to Figure 6.
HES1 (left) and CCL4 (right) expression was assessed in SU-DHL4 cells by qRT-PCR after 150
min of treatment with rituximab (R) relative to untreated control samples (Ctrl). Cells were pre-
treated with the BTK inhibitor ibrutinib (top) or with the Pi3K inhibitor idelalisib (bottom) for 48
hours. Statistical significance was tested by unpaired parametric t-tests based on 4 biological
replicates for each treatment condition. Mean with range is plotted. *<0.05, **<0.01, ***<0.001, ns
= not significant; as calculated by unpaired non-parametric t-tests.
Supplementary Figure S7:
In primary CLL cells rituximab can increase NOTCH1 signaling via its F(ab‘)2 fragments
and via its Fc-fragment.
Related to Figure 6.
Immunoblot detection of the NOTCH1 intracellular domain (NICD1) in SU-DHL4 cells (A) and in
three primary CLL samples (B-D) treated with rituximab (R) for 15, 30 and 60 minutes, rituximab
F(ab‘)2 fragments (R F(ab‘)2;) for 60 minutes, or trastuzumab (Tra) for 60 minutes relative to



































































































































Mean FC CCL2 expression























The increase in HES1 expression after rituximab treatment correlated with the mean fold
change of CCL2 expression, used as surrogate marker for monocyte activation.
Related to Figure 6.
HES1 and CCL2 expression was assessed in 8 individual CLL samples by qRT-PCR after 150
min of treatment with rituximab relative to untreated controls. Two to five biological replicates
were used for each sample and treatment condition. The fold change (FC) of HES1 expression
was plotted against the mean FC of CCL2 expression. Linear regression analysis was used to
test for an association between the increase in HES1 and CCL2 expression.
Transparent Methods 1 
Cells lines and patient samples 2 
The B-cell lines SU-DHL4 derived from a germinal center B-cell type DLBCL (Epstein and 3 
Kaplan, 1979) and MEC1 derived from CLL in prolymphocytoid transformation (Stacchini et 4 
al., 1999) were obtained from American Type Culture Collection (ATCC, Manassas, VA, 5 
USA).  6 
Peripheral blood samples were obtained from CLL patients attending St. Bartholomew’s 7 
Hospital (Barts) and consenting to use of specimens for research. Peripheral blood 8 
mononuclear cells (PBMCs) were isolated via density gradient centrifugation (Lymphoprep®, 9 
Stemcell Technologies®, Vancouver, Canada) and enriched for B-cells via immunomagnetic 10 
beads against CD19 (MACS®, Miltenyi Biotec®, Bergisch Gladbach, Germany). To prevent 11 
activation of the NOTCH1 receptor during the isolation procedure, contact of cells with EDTA 12 
was avoided by the use of heparin monovettes and preparation of EDTA-free MACS sorting 13 
buffer. After sorting, CLL cells were used for downstream experiments immediately. White 14 
blood cell counts for the CLL samples used for Western blot analysis are provided below (as 15 
measured on the day of sample acquisition): 16 
# CLL1  WBC: 158.0 x 109/l 17 
# CLL2  WBC: 409,4 x 109/l 18 
# CLL3  WBC: 73.8 x 109/l 19 
Reagents 20 
Cells were treated with the two anti-CD20 monoclonal antibodies rituximab and 21 
obinutuzumab. Trastuzumab was used as an isotype control. F(ab’)2 fragments were used to 22 
study Fc-independent effects resulting exclusively from CD20 binding. The IgG B-cell 1 
receptor of SU-DHL4 was cross-linked by SB2H2. 2 
Rituximab, trastuzumab and obinutuzumab were obtained from the local pharmacy of St. 3 
Bartholomew’s hospital, London, United Kingdom. SB2H2 and rituximab F(ab’)2 fragments 4 
were in-house productions at the Centre of Cancer Immunology at Southampton University, 5 
Prof. Mark Cragg, and received as gifts. Hybridoma cell lines secreting the respective 6 
monoclonal antibodies were cultured and secreted antibodies were purified from the culture 7 
supernatant using protein A columns (GE Healthcare, Chicago, IL, USA). Purity of in-house 8 
monoclonal antibodies was assessed by electrophoresis (Beckman EP system, Beckman 9 
Coulter, Pasadena, CA, USA). Rituximab F(ab’)2 fragments were produced by standard pepsin 10 
digestions. The kinase inhibitors R406, ibrutinib and idelalisib were purchased from 11 
Selleckchem® at a concentration of 10mM/1ml in DMSO (Houston, TX, USA). 12 
Cell culture 13 
The SU-DHL4 cell line was maintained in Roswell Park Memorial Institute (RPMI) 1640 14 
medium (Sigma-Aldrich®); the MEC1 cell line in Dulbecco’s Modified Eagle Medium 15 
(DMEM; Sigma-Aldrich®). Medium was supplemented with 10% fetal bovine serum (FBS; 16 
Life Technologies®, Carlsbad, CA, USA) and 1% Penicillin/Streptomycin (Sigma-Aldrich®). 17 
Both cell lines were maintained at a concentration of 0.7 x 106 cells/ml at 37 °C and 5% CO2.  18 
Monoclonal antibody treatment of SU-DHL4 cells and primary CLL cells 19 
To assess signaling changes in the B-cell receptor cascade after monoclonal antibody treatment 20 
(CCL4 and CCL3 expression; phosphorylation of SYK, AKT and PRAS40) cells were 21 
re-suspended in their cell culture medium at a concentration of 1 x 106 cells/ml and treated with 22 
the respective antibody at a concentration of 5 μg/ml for 1 h, 2.5 h or 24 h. Whole cell lysates 1 
for protein analysis were obtained after 1 h or 24 h. RNA was isolated after 2.5 h. 2 
To assess short-term changes in NOTCH1 signaling after monoclonal antibody treatment 3 
(HES1 alongside CCL4 expression), SU-DHL4 cells were re-suspended in PBS at a 4 
concentration of 5 x 106 cells/ml. Immediately after re-suspension, cells were treated with the 5 
respective monoclonal antibody at a concentration of 2.5 μg/ml and kept in the incubator at 6 
37 °C and 5% CO2 for 1 h. After 1 h, two volumes of RPMI were added to one volume of PBS 7 
and cells were kept in the incubator for another 1.5 hours before RNA isolation. 8 
To assess long-term changes in NOTCH1 signaling, SU-DHL4 and MEC1 cells were used 9 
directly from the culture medium supplemented with inhibitors or vehicle control for 48 h (see 10 
below). Nuclear cell lysates were used for NICD1 immunoblots. 11 
Treatment of SU-DHL4 and MEC1 cells with kinase inhibitors  12 
The kinases Syk, Btk and Pi3K were inhibited by R406, ibrutinib and idelalisib, respectively. 13 
Cells were exposed to the inhibitors for 48 hours before subsequent experiments were 14 
conducted. Inhibitors were used at the following concentrations: 15 
R406 and idelalisib  5 μM 16 
Ibrutinib   1 μM 17 
DMSO vehicle controls were kept alongside. PBS and culture medium added during the course 18 
of an experiment were supplemented with the respective inhibitor at concentrations mentioned 19 
above or with vehicle control.  20 
Cell viability in each inhibitor and control condition was >90% after 48 hours. 21 
Protein immunoblotting 22 
For SYK, AKT and PRAS40 immunoblotting from whole cell lysates, cells were lysed with 1 
the Qproteome Mammalian Protein Prep Kit (Qiagen®, Hilden, Germany) according to the 2 
manufacturer’s protocol. For NICD1 immunoblotting from nuclear protein fractions, cells were 3 
processed with NE-PER Nuclear and Cytoplasmic Extraction Reagents (Thermo Scientific, 4 
Waltham, MA, USA). Protein concentrations were determined by averaging three to four 5 
technical replicates measured on the NanoDrop® ND-1000 by using the Bradford dye-binding 6 
method (Protein Assay Dye Reagent Concentrate; Bio-Rad Laboratories, Hercules, CA, USA).  7 
Lysates were separated by NuPAGE 4-12% Bis-Tris gels (Thermo Fisher Scientific) and 8 
transferred to PVDF membranes (Immobilon®, 0.45 µm pore size; Burlington, MA, USA) by 9 
wet electroblotting (17 hours, 30 Volts). Membranes were blocked with TBS with 1% skim 10 
milk powder (Sigma; St. Louis, MO, USA) and incubated with primary antibody for 1 hour at 11 
room temperature (see list of antibodies below). Following incubation, each membrane was 12 
washed four times with TBS supplemented with 0.1% Tween® 20 (Sigma-Aldrich, St. Louis, 13 
MO, USA), before incubation with a secondary horseradish peroxidase conjugated goat 14 
anti-rabbit antibody (GE Healthcare). Protein bands were visualized by using ECL Prime 15 
Western Blotting Detection Reagent (GE Healthcare) and the Amersham 600 imager (GE 16 
Healthcare). 17 
The following primary antibodies were used for western blot analysis: 18 
Cleaved NOTCH1 (Val1744)(D3B8) Rabbit mAb   Cell Signaling Technology® 19 
Syk (D3Z1E) XP® Rabbit mAb      Cell Signaling Technology® 20 
Phospho-Zap-70 (Tyr319)/Syk (Tyr352) (65E4) Rabbit mAb  Cell Signaling Technology® 21 
Phospho-Syk (Tyr525/526) (C87C1) Rabbit mAb   Cell Signaling Technology® 22 
Akt (pan) (C67E7) Rabbit mAb      Cell Signaling Technology® 23 
Phospho-Akt (Ser473) (D9E) XP® Rabbit mAb   Cell Signaling Technology® 24 
Phospho-Akt (Thr308) (D25E6) XP® Rabbit mAb   Cell Signaling Technology® 25 
PRAS40 (D23C7) XP® Rabbit mAb     Cell Signaling Technology® 1 
Phospho-PRAS40 (Thr246) (C77D7) Rabbit mAb   Cell Signaling Technology® 2 
GAPDH (D16H11) XP® Rabbit mAb     Cell Signaling Technology® 3 
Anti-Lamin B1 antibody (ab16048) Rabbit polyclonal antibody Abcam® XXX 4 
Quantitative real-time polymerase chain reaction (qRT-PCR) 5 
RNA was isolated by using the RNeasy Mini Kit (Qiagen®). Complementary DNA (cDNA) 6 
was generated from RNA using High-Capacity RNA-to-cDNA Kit® [Thermo Fisher 7 
Scientific®, Waltham, MA, USA] and 100 ng cDNA was subsequently used in 20 μl qRT-PCR 8 
reactions with TaqMan® Gene Expression Assays [Applied Biosystems®, Foster City, CA, 9 
USA]. ACTB or 18S was used as endogenous control in 1:10 dilutions from the cDNA sample 10 
used for target gene analysis. Reactions were performed in triplicates on a QuantStudio™ 7 11 
Flex System [Applied Biosystems®] using the standard thermal cycler protocol. 12 
The following TaqMan® Gene Expression Assays were used: 13 
HES1:  Hs00172878_m1 14 
CCL4:  Hs01092201_m1 15 
CCL3:  Hs00234142_m1 16 
CCL2:  Hs00234140_m1 17 
Fold changes were calculated towards the mean ΔCt-value of all reference samples. 18 
Liquid chromatography tandem-mass spectrometry (LC-MS/MS) based 19 
phosphoproteomics 20 
Briefly, cells were treated with rituximab or obinutuzumab (5 μg/ml) for 0h, 1h or 24 h in 21 
biological triplicates. Cells were lysed, protein concentrations normalized, proteins reduced 22 
and alkylated prior to tryptic digest. Subsequently, digests were desalted and underwent TiO2 23 
based phospho-enrichment. Reconstituted samples were analyzed twice using an automated 1 
data-dependent acquisition on a Q-Exactive Plus mass spectrometer (Thermo Scientific). 2 
Peptide identification was conducted using Mascot Distiller 2.3.2 / Mascot Daemon 2.5 and 3 
label-free peptide quantification using in-house developed Peak statistics calculator (PESCAL) 4 
software. Extracted ion chromatograms were generated for each phosphopeptide ion and 5 
quantification values calculated by measuring areas under the curve. Analytical replicated 6 
(N=2) were averaged for each biological replicate (N=3). Quantified peptide ions that 7 
possessed the same phosphorylation site were combined. Differences in phosphorylation levels 8 
between each treatment group and the untreated control group were tested for significance by 9 
unpaired non-parametric t-tests conducted in GraphPad Prism version 8.1.1. Kinase activity 10 
was inferred by kinase substrate enrichment analysis (KSEA) as previously described (Casado 11 
et al., 2013). Pathway enrichment analysis was conducted through the Database for Annotation, 12 
Visualization and Integrated Discovery (DAVID) v6.8 (Huang da et al., 2009a; Huang da et 13 
al., 2009b). LC-MS/MS raw data is publicly available (PRIDE ID PXD023572). 14 
A more detailed description of sample preparation, LC-MS/MS analysis and data processing is 15 
provided below. 16 
Mass spectrometry sample preparation 17 
1 x 107 SU-DHL-4 cells were either treated with rituximab or obinutuzumab for 1 or 24 hours, 18 
using a monoclonal antibody concentration of 5 μg/ml. Untreated controls were run in parallel. 19 
All conditions were run in biological triplicates.  20 
Post antibody treatment, cell lysis, protein normalization, digestion, and 21 
phosphopeptide-enrichment were performed as previously described43. Briefly, cells were 22 
washed three times in cold PBS supplemented with 1 mM Na3VO4 and 1 mM NaF. Cells were 23 
then lysed in urea buffer (8 M urea in 20 mM HEPES pH 8.0 supplemented with 1 mM 24 
Na3VO4, 1 mM NaF, 1 mM Na4P2O7 and 1 mM sodium β-glycerophosphate). Cell extracts 1 
were sonicated (10 cycles of 30 sec on and 40 sec off; Bioruptor® Plus, Diagenode, Liege, 2 
Belgium). Insoluble material was removed by centrifugation at 15,000 rpm for 10 min at 4 ˚C. 3 
Protein was quantified by bicinchoninic acid (BCA) assay (PierceTM BCA Protein Assay Kit, 4 
Thermo Fisher Scientific), and 350 µg of protein was reduced and alkylated by sequential 5 
incubation with 10 mM DTT and 16.6 mM iodoacetamyde for 40 minutes. Urea concentration 6 
was diluted to 1.44 M with 20 mM HEPES (pH 8.0), prior to the addition of preconditioned 7 
trypsin beads as per manufacturers specifications [(Immobilized Trypsin, TPCK Treated, 8 
Thermo Fisher Scientific)] and incubation for 18h at 37 ˚C. Trypsin beads were removed by 9 
centrifugation at 2,000 x g for 5 min at 4˚C.  10 
Peptide solutions were desalted using 10 mg OASIS-HLB cartridges (Waters, Manchester, 11 
UK). Cartridges were activated with ACN (100%) and equilibrated with 1.5 mL washing 12 
solution (1% ACN, 0.1% TFA). After loading the samples, cartridges were washed with 1 mL 13 
of washing solution. Peptides were eluted with 500 µL of glycolic acid buffer (1 M glycolic 14 
acid, 50% ACN, 5% TFA). 15 
To enrich phosphopeptides, sample volumes were normalised to 600 µL using glycolic acid 16 
buffer (1 M glycolic acid, 80% ACN, 5% TFA) and 50 µL of TiO2 beads [(50% slurry in 1% 17 
TFA), GL Sciences, Shinjuku, Tokio, Japan] were added to the peptide mixture and incubated 18 
for 5 min at room temperature with agitation and centrifuged for 30 s at 1,500 x g. Pelleted 19 
TiO2 beads were then loaded into an empty PE-filtered spin-tip (Glygen, Columbia, MD, USA) 20 
prewashed with ACN and packed by centrifugation at 1500 x g for 3 min. The remaining 21 
supernatants were then applied to respective spin tips by centrifugation at 1,500 x g for 2 min, 22 
and then sequentially washed by 3 min centrifugation at 1,500 x g with glycolic acid buffer, 23 
100 mM ammonium acetate (25% ACN) and 10% ACN. For phosphopeptide recovery, 24 
peptides were eluted with 5% ammonium water. Eluents were dried in a speed vac and peptide 1 
pellets stored at -80 ˚C.  2 
LC-MS/MS analysis 3 
For LC-MS/MS analysis, peptides were resuspended in 12 µL of reconstitution buffer 4 
(97% H20, 3% ACN, 0.1% TFA, 50 fmol/µl-1 enolase peptide digest), sonicated for 1 min at 5 
room temperature and placed in the autosampler (4 °C) until analyzed. Each sample was 6 
analyzed twice (4 μl injections). The LC-MS/MS system consisted of a nanoflow ultrahigh 7 
pressure liquid chromatography system (UltiMateTM 3000 RSLCnano, Dionex, Sunnyvale, 8 
CA, USA) coupled to a Q-Exactive Plus (Thermo Fisher Scientific).  9 
The LC system used mobile phases A (3% ACN: 0.1% FA) and B (100% ACN; 0.1% FA). 10 
Peptides were loaded onto a μ-pre-column (Thermo Fisher Scientific) and separated in an 11 
analytical column (EASY-Spray, Thermo Fisher Scientific). The gradient was 1% B for 5 min, 12 
1% B to 35% B over 60 min. Following elution, the column was washed with 85% B for 7 min 13 
and equilibrated with 3% B for 7 min at a flow rate of 0.25 µL/min. Peptides were nebulized 14 
into the online connected Q-Exactive Plus system operating with a 2.1s duty cycle. Acquisition 15 
of full scan survey spectra (m/z 375-1,500) with a 70,000 FWHM resolution was followed by 16 
data-dependent acquisition in which the 15 most intense ions were selected for HCD (higher 17 
energy collisional dissociation) and MS/MS scanning (200-2,000 m/z) with a resolution of 18 
17,500 FWHM. A 30 sec dynamic exclusion period was enabled with an exclusion list with 10 19 
ppm mass window. Overall duty cycle generated chromatographic peaks of approximately 30 20 
sec at the base, which allowed the construction of extracted ion chromatograms (XICs) with at 21 
least 10 data points.  22 
Peptide identification and quantification 23 
Mascot Distiller 2.3.2 was used to fit an ideal isotopic distribution to the MS/MS data to 1 
maximize peptide identification. Mascot Daemon 2.5 search engine was used to match peaks 2 
to peptides in proteins present in the Uniprot/SwissProt Database (human species). The process 3 
was automated with Mascot Daemon 2.5.0. Mass tolerance was set to ± 10 ppm, with variable 4 
modifications phospho (ST), phospho (Y), glnpyro-glu (N-term Q) and oxidation (M) 5 
included in the search. Carbamidomethyl (C) as fixed modification. Trypsin was selected as 6 
digestion enzyme and 2 miss cleavages were allowed. Sites of modification were reported when 7 
they had delta scores >10. 8 
Peptide and subsequent protein quantification was achieved using in-house developed 9 
PESCAL (Peak statistics calculator) software (Cutillas, 2017). PESCAL constructs extracted 10 
ion chromatograms (XICs) for each peptide identified with the MASCOT search engine. With 11 
each constructed XIC, peak heights could be calculated. These peptide peak heights were then 12 
normalized to the sum of the intensities for each individual sample and the average fold change 13 
between conditions could be determined. Statistical significance between conditions was 14 
considered significant when the Student T-Tests produced P <0.05. Further data processing 15 
and analysis was conducted within Microsoft Excel (2007/2010) or R (v3.3.2/v3.4.1 – 16 
reshape2, ggplot2, gplots, readXL, Hmisc and limma packages). 17 
Kinase substrate enrichment analysis (KSEA) was performed as described before (Casado et 18 
al., 2013). Briefly, peptides differentially phosphorylated between a set of samples were 19 
grouped into substrate sets known to be phosphorylated by a specific kinase as annotated in the 20 
PhosphoSite, Phospho.ELM, and PhosphoPOINT databases (Hornbeck et al., 2015; Dinkel et 21 
al., 2011; Yang et al., 2008). To infer enrichment of substrate groups across sets of samples the 22 
hypergeometric test was used, followed by Benjamini Hochberg multiple testing correction. 23 
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